Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens.

Tong X, Smith J, Bukreyeva N, Koma T, Manning JT, Kalkeri R, Kwong AD, Paessler S.

Antiviral Res. 2018 Jan;149:34-40. doi: 10.1016/j.antiviral.2017.11.004. Epub 2017 Nov 8.

PMID:
29126899
2.

Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit.

Byrn RA, Jones SM, Bennett HB, Bral C, Clark MP, Jacobs MD, Kwong AD, Ledeboer MW, Leeman JR, McNeil CF, Murcko MA, Nezami A, Perola E, Rijnbrand R, Saxena K, Tsai AW, Zhou Y, Charifson PS.

Antimicrob Agents Chemother. 2015 Mar;59(3):1569-82. doi: 10.1128/AAC.04623-14. Epub 2014 Dec 29.

3.

Nonstructural protein 5A (NS5A) and human replication protein A increase the processivity of hepatitis C virus NS5B polymerase activity in vitro.

Mani N, Yuzhakov A, Yuzhakov O, Coll JT, Black J, Saxena K, Fulghum JR, Lippke JA, Rao BG, Rijnbrand R, Kwong AD.

J Virol. 2015 Jan;89(1):165-80. doi: 10.1128/JVI.01677-14. Epub 2014 Oct 15.

4.

Barrier to resistance: lessons from 2 direct-acting hepatitis C virus inhibitors, MK-5172 and Sofosbuvir.

Tong X, Kwong AD.

Clin Infect Dis. 2014 Dec 15;59(12):1675-7. doi: 10.1093/cid/ciu700. Epub 2014 Sep 28. No abstract available.

PMID:
25266288
5.

Telaprevir-based treatment effects on hepatitis C virus in liver and blood.

Talal AH, Dimova RB, Zhang EZ, Jiang M, Penney MS, Sullivan JC, Botfield MC, Chakilam A, Sawant R, Cervini CM, Zeremski M, Jacobson IM, Kwong AD.

Hepatology. 2014 Dec;60(6):1826-37. doi: 10.1002/hep.27202. Epub 2014 Jul 31.

6.

The HCV Revolution Did Not Happen Overnight.

Kwong AD.

ACS Med Chem Lett. 2014 Mar 13;5(3):214-220.

7.

Restoration of the activated Rig-I pathway in hepatitis C virus (HCV) replicon cells by HCV protease, polymerase, and NS5A inhibitors in vitro at clinically relevant concentrations.

Kalkeri G, Lin C, Gopilan J, Sloan K, Rijnbrand R, Kwong AD.

Antimicrob Agents Chemother. 2013 Sep;57(9):4417-26. doi: 10.1128/AAC.00399-13. Epub 2013 Jul 8.

8.

Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.

Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong AD, Picchio G, Kieffer TL.

J Virol. 2013 Feb;87(3):1544-53. doi: 10.1128/JVI.02294-12. Epub 2012 Nov 14.

9.

Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment.

Sullivan JC, Zhang EZ, Bartels DJ, Tigges A, Dorrian JL, Kwong AD, Kieffer TL.

Virol J. 2012 Aug 6;9:147. doi: 10.1186/1743-422X-9-147.

10.

Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.

Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, Spanks J, Dorrian J, Jiang M, Adiwijaya B, Ghys A, Beumont M, Kauffman RS, Adda N, Jacobson IM, Sherman KE, Zeuzem S, Kwong AD, Picchio G.

PLoS One. 2012;7(4):e34372. doi: 10.1371/journal.pone.0034372. Epub 2012 Apr 12.

11.

Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.

Kwong AD, Kauffman RS, Hurter P, Mueller P.

Nat Biotechnol. 2011 Nov 8;29(11):993-1003. doi: 10.1038/nbt.2020.

PMID:
22068541
12.

HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a.

Lange CM, Susser S, Herrmann E, Karey U, Kieffer TL, Kwong AD, Schinkel J, Reesink HW, Zeuzem S, Sarrazin C.

Scand J Gastroenterol. 2011 Nov;46(11):1362-8. doi: 10.3109/00365521.2011.605465. Epub 2011 Aug 5.

PMID:
21815864
13.

Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG.

Kwong AD, Najera I, Bechtel J, Bowden S, Fitzgibbon J, Harrington P, Kempf D, Kieffer TL, Koletzki D, Kukolj G, Lim S, Pilot-Matias T, Lin K, Mani N, Mo H, O'Rear J, Otto M, Parkin N, Pawlotsky JM, Petropoulos C, Picchio G, Ralston R, Reeves JD, Schooley RT, Seiwert S, Standring D, Stuyver L, Sullivan J, Miller V; Forum for Collaborative Human Immunodeficiency Virus Research; HCV Drug Development Advisory Group (HCV DRAG); Sequence Analysis Working Group (SAWG); Phenotype Analysis Working Group (PAWG).

Gastroenterology. 2011 Mar;140(3):755-60. doi: 10.1053/j.gastro.2011.01.029. Epub 2011 Jan 19. No abstract available.

PMID:
21255574
14.

A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants.

Adiwijaya BS, Herrmann E, Hare B, Kieffer T, Lin C, Kwong AD, Garg V, Randle JC, Sarrazin C, Zeuzem S, Caron PR.

PLoS Comput Biol. 2010 Apr 15;6(4):e1000745. doi: 10.1371/journal.pcbi.1000745.

15.

Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).

Kieffer TL, Kwong AD, Picchio GR.

J Antimicrob Chemother. 2010 Feb;65(2):202-12. doi: 10.1093/jac/dkp388. Epub 2009 Nov 10. Review.

PMID:
19903720
16.

Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors.

Kwong AD, McNair L, Jacobson I, George S.

Curr Opin Pharmacol. 2008 Oct;8(5):522-31. doi: 10.1016/j.coph.2008.09.007. Epub 2008 Oct 17. Review.

PMID:
18835365
17.

Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.

Bartels DJ, Zhou Y, Zhang EZ, Marcial M, Byrn RA, Pfeiffer T, Tigges AM, Adiwijaya BS, Lin C, Kwong AD, Kieffer TL.

J Infect Dis. 2008 Sep 15;198(6):800-7. doi: 10.1086/591141.

PMID:
18637752
18.

Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.

Zhou Y, Bartels DJ, Hanzelka BL, Müh U, Wei Y, Chu HM, Tigges AM, Brennan DL, Rao BG, Swenson L, Kwong AD, Lin C.

Antimicrob Agents Chemother. 2008 Jan;52(1):110-20. Epub 2007 Oct 15.

19.

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.

Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD, Zeuzem S.

Hepatology. 2007 Sep;46(3):631-9.

PMID:
17680654
20.

Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha.

Zhou Y, Müh U, Hanzelka BL, Bartels DJ, Wei Y, Rao BG, Brennan DL, Tigges AM, Swenson L, Kwong AD, Lin C.

J Biol Chem. 2007 Aug 3;282(31):22619-28. Epub 2007 Jun 6.

21.

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.

Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Müh U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD.

Gastroenterology. 2007 May;132(5):1767-77. Epub 2007 Feb 21.

PMID:
17484874
22.

Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.

Lin C, Kwong AD, Perni RB.

Infect Disord Drug Targets. 2006 Mar;6(1):3-16. Review.

PMID:
16787300
23.
24.

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease.

Perni RB, Almquist SJ, Byrn RA, Chandorkar G, Chaturvedi PR, Courtney LF, Decker CJ, Dinehart K, Gates CA, Harbeson SL, Heiser A, Kalkeri G, Kolaczkowski E, Lin K, Luong YP, Rao BG, Taylor WP, Thomson JA, Tung RD, Wei Y, Kwong AD, Lin C.

Antimicrob Agents Chemother. 2006 Mar;50(3):899-909.

25.

Viral and cellular RNA helicases as antiviral targets.

Kwong AD, Rao BG, Jeang KT.

Nat Rev Drug Discov. 2005 Oct;4(10):845-53. Review.

PMID:
16184083
26.

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

Lin C, Gates CA, Rao BG, Brennan DL, Fulghum JR, Luong YP, Frantz JD, Lin K, Ma S, Wei YY, Perni RB, Kwong AD.

J Biol Chem. 2005 Nov 4;280(44):36784-91. Epub 2005 Aug 8.

28.

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms.

Lin C, Lin K, Luong YP, Rao BG, Wei YY, Brennan DL, Fulghum JR, Hsiao HM, Ma S, Maxwell JP, Cottrell KM, Perni RB, Gates CA, Kwong AD.

J Biol Chem. 2004 Apr 23;279(17):17508-14. Epub 2004 Feb 6.

29.

Inhibitors of hepatitis C virus NS3.4A protease: an overdue line of therapy.

Perni RB, Kwong AD.

Prog Med Chem. 2002;39:215-55. Review. No abstract available.

PMID:
12536674
31.

Development of a hepatitis C virus RNA helicase high throughput assay.

Kwong AD, Risano C.

Methods Mol Med. 2000;24:97-116. doi: 10.1385/1-59259-245-7:97.

PMID:
21331903
32.

Structure and function of hepatitis C virus NS3 helicase.

Kwong AD, Kim JL, Lin C.

Curr Top Microbiol Immunol. 2000;242:171-96. Review.

PMID:
10592661
33.

Hepatitis C virus NS3/4A protease.

Kwong AD, Kim JL, Rao G, Lipovsek D, Raybuck SA.

Antiviral Res. 1999 Feb;41(1):67-84. Review.

PMID:
10321580
34.

Generation of recombinant herpes simplex virus ampiicons.

Hong Z, Kwong AD.

Methods Mol Med. 1999;19:553-64. doi: 10.1385/0-89603-521-2:553.

PMID:
21374396
35.

Hepatitis C virus NS3/4A protease.

Kwong AD, Kim JL, Rao G, Lipovsek D, Raybuck SA.

Antiviral Res. 1998 Dec;40(1-2):1-18. Review.

PMID:
9864043
36.

In situ PCR for in vivo detection of foreign genes transferred into rat brain.

Yin J, Kaplitt MG, Kwong AD, Pfaff DW.

Brain Res. 1998 Feb 9;783(2):347-54.

PMID:
9507188
37.

Serine protease of hepatitis C virus expressed in insect cells as the NS3/4A complex.

Sali DL, Ingram R, Wendel M, Gupta D, McNemar C, Tsarbopoulos A, Chen JW, Hong Z, Chase R, Risano C, Zhang R, Yao N, Kwong AD, Ramanathan L, Le HV, Weber PC.

Biochemistry. 1998 Mar 10;37(10):3392-401.

PMID:
9521660
38.

Production of recombinant herpes simplex virus protease in 10-L stirred vessels using a baculovirus-insect cell expression system.

Schwartz JL, Ferrari EB, Terracciano J, Troyanovich J, Gunnarsson I, Wright-Minogue J, Chen JW, Kwong AD.

J Ind Microbiol Biotechnol. 1997 Aug;19(2):87-91.

PMID:
9366090
39.

SCH 43478 and analogs: in vitro activity and in vivo efficacy of novel agents for herpesvirus type 2.

Albin R, Chase R, Risano C, Lieberman M, Ferrari E, Skelton A, Buontempo P, Cox S, DeMartino J, Wright-Minogue J, Jirau-Lucca G, Kelly J, Afonso A, Kwong AD, Rozhon EJ, O'Connell JF.

Antiviral Res. 1997 Aug;35(3):139-46.

PMID:
9298753
40.

Structure of the hepatitis C virus RNA helicase domain.

Yao N, Hesson T, Cable M, Hong Z, Kwong AD, Le HV, Weber PC.

Nat Struct Biol. 1997 Jun;4(6):463-7.

PMID:
9187654
41.
42.

Enzymatic characterization of hepatitis C virus NS3/4A complexes expressed in mammalian cells by using the herpes simplex virus amplicon system.

Hong Z, Ferrari E, Wright-Minogue J, Chase R, Risano C, Seelig G, Lee CG, Kwong AD.

J Virol. 1996 Jul;70(7):4261-8.

44.

Preproenkephalin promoter yields region-specific and long-term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector.

Kaplitt MG, Kwong AD, Kleopoulos SP, Mobbs CV, Rabkin SD, Pfaff DW.

Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8979-83.

45.

Minireview: the herpes simplex virus amplicon--a versatile defective virus vector.

Frenkel N, Singer O, Kwong AD.

Gene Ther. 1994;1 Suppl 1:S40-6. Review.

PMID:
8542394
46.

Synthesis of DNA by DNA polymerase epsilon in vitro.

Lee SH, Pan ZQ, Kwong AD, Burgers PM, Hurwitz J.

J Biol Chem. 1991 Nov 25;266(33):22707-17.

47.
48.

The in vitro replication of DNA containing the SV40 origin.

Hurwitz J, Dean FB, Kwong AD, Lee SH.

J Biol Chem. 1990 Oct 25;265(30):18043-6. Review. No abstract available.

49.

The herpes simplex virus virion host shutoff function.

Kwong AD, Frenkel N.

J Virol. 1989 Nov;63(11):4834-9.

50.

Supplemental Content

Loading ...
Support Center